Join us for a workshop on August 26, hosted by Life Sciences Central [powered by MaRS, OBIO® and TIAP] on biotech VC valuation.
Raising venture capital is about much more than negotiating a valuation. In early-stage biotech, valuation reflects scientific risk, development milestones, financing strategy, ownership, and the potential to create future value.
Led by Xin Hang (Senior Principal at CTI Life Sciences Fund and MaRS' Advisor), this workshop is designed primarily for first-time biotech founders and CEOs preparing to raise institutional capital.
What to expect from the session:
Practical, VC-focused framework for understanding how biotech companies are valued and financed.
How venture investors evaluate opportunities, assess risk, determine ownership targets, estimate valuation, and review financing terms.
Forecasting, common valuation methodologies, term sheet economics, and fundraising strategy—giving founders a better understanding of what drives investment decisions.
This event is free, but registration is subject to approval.